SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Schloss, P.
Right arrow Articles by Williams, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schloss, P.
Right arrow Articles by Williams, D. C.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Antidepressants
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The serotonin transporter: a primary target for antidepressant drugs

Patrick Schloss

Biochemistry Department, University of Dublin, Trinity College, Dublin 2, Ireland

D. Clive Williams

Biochemistry Department, University of Dublin, Trinity College, Dublin 2, Ireland

The serotoninergic system is known to modulate mood, emotion, sleep and appetite and thus is implicated in the control of numerous behavioural and physiological functions. Decreased serotoninergic neurotransmission has been proposed to play a key role in the aetiology of depression. The concentration of synaptic serotonin is controlled directly by its reuptake into the pre-synaptic terminal and, thus, drugs blocking serotonin transport have been successfully used for the treatment of depression. In addition to tricyclic antidepressants (TCAs; e.g. imipramine) which also block noradrenaline reuptake, highly specific serotonin reuptake inhibitors (SSRIs) such as fluoxetine and paroxetine have been developed, which are increasingly prescribed for depressed patients. The mode of action of these antidepressant drugs on their direct target, the serotonin transport protein, and possible regulatory mechanisms with respect to long-term alleviation of depression, although having been investigated both neurobiologically and clinically over the last years, are not yet understood. The cloning of the cDNA encoding the serotonin transporter has allowed a more precise characterization of this protein at the molecular level. This will show how antidepressants act at this target, thereby affecting the biochemical, pharmacological and electrophysiological properties of the serotoninergic system and give an introduction of how they might exert their therapeutic effect. This review gives an overview of the recent developments in this field, discusses mechanisms of antidepressant action on this target, and also possible interactions with other components of serotoninergic neurotransmission.

Key Words: antidepressant drugs • inhibition • regulation • serotonin transporter

Journal of Psychopharmacology, Vol. 12, No. 2, 115-121 (1998)
DOI: 10.1177/026988119801200201


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
FASEB J.Home page
T. Lau, S. Horschitz, S. Berger, D. Bartsch, and P. Schloss
Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons
FASEB J, June 1, 2008; 22(6): 1702 - 1714.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
Z. Zhou, J. Zhen, N. K. Karpowich, R. M. Goetz, C. J. Law, M. E. A. Reith, and D.-N. Wang
LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake
Science, September 7, 2007; 317(5843): 1390 - 1393.
[Abstract] [Full Text] [PDF]


Home page
Vet Rec.Home page
D. Cakiroglu, Y. Meral, A. A. Sancak, and G. Cifti
Relationship between the serum concentrations of serotonin and lipids and aggression in dogs
Vet Rec., July 14, 2007; 161(2): 59 - 61.
[Abstract] [Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
N. C. Brahm, K. C. Farmer, and R. C. Brown
Risperidone for the treatment of fecal smearing in a developmentally disabled adult
Am. J. Health Syst. Pharm., February 15, 2007; 64(4): 382 - 384.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. K. Muller, O. Wiborg, and J. Haase
Subcellular Redistribution of the Serotonin Transporter by Secretory Carrier Membrane Protein 2
J. Biol. Chem., September 29, 2006; 281(39): 28901 - 28909.
[Abstract] [Full Text] [PDF]



Advertisement